Lamictal tablets 50 mg. №28

Description

Lamictal 50 mg Composition
active substance: lamotrigine;

1 tablet contains lamotrigine 50 mg;

excipients: calcium carbonate, low-substituted hydroxypropyl cellulose, aluminum magnesium silicate, sodium starch (type A), povidone K30, sodium saccharin, blackcurrant flavor, magnesium stearate.

Lamictal 50 mg Dosage form
The tablets are dispersed.

Basic physical and chemical properties: multifaceted supereleptic with a smooth surface, tablets with the smell of black currant. On the one hand, the tablets are embossed with GSCX7, on the other – the dose of the drug. Marbling is allowed on the surface of the tablets.

Lamictal 50 mg Pharmacotherapeutic group
Antiepileptic drugs. Lamotrigine. ATX code N03A X09.

Pharmacodynamics
Lamotrigine is an anticonvulsant drug, the mechanism of action of which is associated with the blocking of voltage-dependent sodium channels of the presynaptic membranes of neurons in the phase of slow inactivation and inhibition of the excessive release of glutamate (an amino acid that plays a significant role in the development of an epileptic seizure).

Pharmacokinetics
After administration, the drug is rapidly and completely absorbed from the gastrointestinal tract. The maximum concentration in blood plasma is reached after 2.5 hours.

Lamotrigine is actively metabolized, the main metabolite is N-glucuronide. The average elimination half-life in adults is 29 hours. Lamictal has a linear pharmacological profile. It is excreted mainly in the form of metabolites and partially unchanged, mainly in the urine. In children, the half-life is shorter than in adults.

Indications
Epilepsy.

Adults and children over the age of 13

Adjunctive therapy or monotherapy for partial and generalized seizures of epilepsy, including tonic-clonic seizures.

Seizures associated with Lennox-Gastaut syndrome. Lamictal is prescribed as an adjunctive therapy, but in Lennox-Gastaut syndrome, it can be prescribed as an initial antiepileptic drug (PEP).

Children aged 2 to 12

Adjunctive therapy for partial and generalized seizures of epilepsy, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome.

Monotherapy for typical absences.

Bipolar disorder.

Adults (from 18 years old)

Prevention of depressive conditions in patients with bipolar I disorder who mainly suffer from depressive conditions.

Lamictal is not indicated for the emergency treatment of manic or depressive episodes.

Contraindications
Lamictal is contraindicated in patients with known hypersensitivity to lamotrigine or any other component of the drug.

Interaction with other medicinal products and other types of interactions
It was found that uridine 5′-diphospho (UDP) -glucuronyl transferase (UGO) is an enzyme that is responsible for the metabolism of lamotrigine. Thus, drugs that induce or inhibit hepatic impairment may affect the clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are known to induce UGO, can also increase the metabolism of lamotrigine.

Those drugs that have been proven to have a clinically significant effect on the metabolism of lamotrigine are outlined in Table 1. Specific dosage recommendations for these drugs are presented in the Dosage and Administration section.

There is no evidence that lamotrigine can cause clinically significant stimulation or suppression of cytochrome P450 enzymes. Lamotrigine can induce its own metabolism, but this effect is moderate and does not have significant clinical consequences.